Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell

Elara Capital which has reduce rating on stock said FY19 operating performance remained weak, given lack of meaningful US sales.

from Moneycontrol http://bit.ly/2Kc5juY